Literature DB >> 9315105

A novel protein with strong homology to the tumor suppressor p53.

H Schmale1, C Bamberger.   

Abstract

The p53 tumor suppressor orchestrates a number of important genes involved in cell-cycle control and apoptosis. Mice deficient for p53 show a high incidence of cancer but are developmentally normal suggesting that compensatory mechanisms exist in embryogenesis and differentiation. The new KET protein is the first mammalian protein with strong homology to p53 in all evolutionary conserved regions. This conservation makes a functional redundancy of the two proteins in cell-cycle control possible. KET is expressed during embryonic development and in certain adult tissues. Among all of the known p53 proteins of different species KET is most closely related to that found in squid. The relationship between KET and the invertebrate p53 protein sheds light on the evolutionary origin of p53. KET appears to be an ancestral p53-related protein in vertebrates with a possible role in development and differentiation while the ubiquitously expressed p53 protein attained its general role as 'guardian of the genome' during evolution.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315105     DOI: 10.1038/sj.onc.1201500

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

1.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization.

Authors:  M G Mateu; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

4.  Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.

Authors:  Elia Guadagno; Marialaura Del Basso De Caro; Sara Pignatiello; Concetta Sciammarella; Domenico Solari; Paolo Cappabianca; Francesco Maiuri; Flavia Dones
Journal:  J Neurooncol       Date:  2016-07-09       Impact factor: 4.130

5.  E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.

Authors:  S Wienzek; J Roth; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Differential recognition of response elements determines target gene specificity for p53 and p63.

Authors:  Motonobu Osada; Hannah Lui Park; Yuichi Nagakawa; Keishi Yamashita; Alexey Fomenkov; Myoung Sook Kim; Guojun Wu; Shuji Nomoto; Barry Trink; David Sidransky
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

7.  A p53-type response element in the GDF15 promoter confers high specificity for p53 activation.

Authors:  Motonobu Osada; Hannah Lui Park; Min Joo Park; Jun-Wei Liu; Guojun Wu; Barry Trink; David Sidransky
Journal:  Biochem Biophys Res Commun       Date:  2007-01-25       Impact factor: 3.575

Review 8.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

Review 9.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

10.  Upregulation of cell adhesion through delta Np63 silencing in human 5637 bladder cancer cells.

Authors:  Yun-Feng He; Dai-Yin Tian; Zheng-Jin Yi; Zhi-Kang Yin; Chun-Li Luo; Wei Tang; Xiao-Hou Wu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.